SHANGHAI – The Chinese-American joint venture Kunshan Riboquark Pharmaceutical Technology Co. Ltd. has raised ¥42 million (US$7 million) in venture capital financing to develop QPI-1007, an ocular neuroprotectant that uses small interfering RNA technology (siRNA) to stop the progression of glaucoma.